FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2745423935> ?p ?o ?g. }

• W2745423935 endingPage "201" @default.
• W2745423935 startingPage "194" @default.
• W2745423935 abstract "Comparar el efecto de diferentes hipoglucemiantes en indicadores analíticos y ecográficos de la esteatosis hepática no alcohólica (EHNA) en pacientes con diabetes tipo 2 no controlados solo con metformina. Estudio prospectivo de pacientes diabéticos tratados con metformina, en combinación con gliclazida, pioglitazona, sitagliptina, exenatida o liraglutida. En el momento basal y a los 6 meses la EHNA fue valorada por ecografía abdominal y se calculó el índice de fibrosis de la EHNA. Cincuenta y ocho pacientes completaron los 6 meses de seguimiento: 15 recibieron gliclazida, 13 pioglitazona, 15 sitagliptina, 7 exenatida y 8 liraglutida. La EHNA afectó basalmente al 57,8% de los casos y su evolución ecográfica varió dependiendo de la evolución del peso (p = 0,009) y de la cintura (p = 0,012). Los porcentajes de sujetos que experimentaron una mejoría ecográfica en los diferentes grupos de tratamiento fueron: 33,3% con gliclazida, 37,5% con pioglitazona, 45,5% con sitagliptina, 80% con exenatida y 33% con liraglutida (p = 0,28). La evolución ecográfica cualitativa de la EHNA en el paciente diabético tratado con metformina en combinación con otros hipoglucemiantes está vinculada a la evolución del peso y del perímetro de cintura. Son precisos ensayos clínicos de larga duración para evaluar si las terapias incretínicas se asocian a mejores resultados hepáticos que otras terapias hipoglucemiantes. To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone. Prospective study of diabetic patients treated with metformin in combination with gliclazide, pioglitazone, sitagliptin, exenatide, or liraglutide. NAFLD was assessed by abdominal ultrasound and NAFLD fibrosis score was calculated at baseline and 6 months. Fifty-eight patients completed 6 months of follow-up: 15 received gliclazide, 13 pioglitazone, 15 sitagliptin, 7 exenatide, and 8 liraglutide. NAFLD affected 57.8% of patients at baseline, and its ultrasonographic course varied depending on changes in weight (P = .009) and waist circumference (P = .012). The proportions of patients who experienced ultrasonographic improvement in the different treatment groups were: 33.3% with gliclazide, 37.5% with pioglitazone, 45.5% with sitagliptin, 80% with exenatide, and 33% with liraglutide (P = .28). Qualitative ultrasonographic NAFLD improvement in diabetic patients treated with metformin in combination with other hypoglycemic drugs is associated to change over time in weight and waist circumference. Long-term clinical trials are needed to assess whether incretin therapies result in better liver outcomes than other hypoglycemic therapies." @default.
• W2745423935 created "2017-08-31" @default.
• W2745423935 creator A5007023490 @default.
• W2745423935 creator A5011588952 @default.
• W2745423935 creator A5025547715 @default.
• W2745423935 creator A5032647006 @default.
• W2745423935 creator A5033965582 @default.
• W2745423935 creator A5057279900 @default.
• W2745423935 creator A5086421384 @default.
• W2745423935 creator A5088155831 @default.
• W2745423935 creator A5091840746 @default.
• W2745423935 date "2016-05-01" @default.
• W2745423935 modified "2023-10-16" @default.
• W2745423935 title "Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto" @default.
• W2745423935 cites W1503584123 @default.
• W2745423935 cites W1622799587 @default.
• W2745423935 cites W1963683487 @default.
• W2745423935 cites W1968002849 @default.
• W2745423935 cites W1973493210 @default.
• W2745423935 cites W1983181715 @default.
• W2745423935 cites W2000545769 @default.
• W2745423935 cites W2002757015 @default.
• W2745423935 cites W2006710454 @default.
• W2745423935 cites W2025106732 @default.
• W2745423935 cites W2031891480 @default.
• W2745423935 cites W2036919886 @default.
• W2745423935 cites W2041468536 @default.
• W2745423935 cites W2047420371 @default.
• W2745423935 cites W2059196301 @default.
• W2745423935 cites W2070710390 @default.
• W2745423935 cites W2078875958 @default.
• W2745423935 cites W2082849768 @default.
• W2745423935 cites W2085970285 @default.
• W2745423935 cites W2097270759 @default.
• W2745423935 cites W2100358697 @default.
• W2745423935 cites W2112496618 @default.
• W2745423935 cites W2126919962 @default.
• W2745423935 cites W2147042329 @default.
• W2745423935 cites W2151253117 @default.
• W2745423935 cites W2157338541 @default.
• W2745423935 cites W2171294019 @default.
• W2745423935 cites W2171407792 @default.
• W2745423935 doi "https://doi.org/10.1016/j.endonu.2016.01.006" @default.
• W2745423935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26976710" @default.
• W2745423935 hasPublicationYear "2016" @default.
• W2745423935 type Work @default.
• W2745423935 sameAs 2745423935 @default.
• W2745423935 citedByCount "15" @default.
• W2745423935 countsByYear W27454239352017 @default.
• W2745423935 countsByYear W27454239352018 @default.
• W2745423935 countsByYear W27454239352019 @default.
• W2745423935 countsByYear W27454239352020 @default.
• W2745423935 countsByYear W27454239352021 @default.
• W2745423935 countsByYear W27454239352022 @default.
• W2745423935 countsByYear W27454239352023 @default.
• W2745423935 crossrefType "journal-article" @default.
• W2745423935 hasAuthorship W2745423935A5007023490 @default.
• W2745423935 hasAuthorship W2745423935A5011588952 @default.
• W2745423935 hasAuthorship W2745423935A5025547715 @default.
• W2745423935 hasAuthorship W2745423935A5032647006 @default.
• W2745423935 hasAuthorship W2745423935A5033965582 @default.
• W2745423935 hasAuthorship W2745423935A5057279900 @default.
• W2745423935 hasAuthorship W2745423935A5086421384 @default.
• W2745423935 hasAuthorship W2745423935A5088155831 @default.
• W2745423935 hasAuthorship W2745423935A5091840746 @default.
• W2745423935 hasConcept C138885662 @default.
• W2745423935 hasConcept C15708023 @default.
• W2745423935 hasConcept C29456083 @default.
• W2745423935 hasConcept C71924100 @default.
• W2745423935 hasConceptScore W2745423935C138885662 @default.
• W2745423935 hasConceptScore W2745423935C15708023 @default.
• W2745423935 hasConceptScore W2745423935C29456083 @default.
• W2745423935 hasConceptScore W2745423935C71924100 @default.
• W2745423935 hasIssue "5" @default.
• W2745423935 hasLocation W27454239351 @default.
• W2745423935 hasLocation W27454239352 @default.
• W2745423935 hasOpenAccess W2745423935 @default.
• W2745423935 hasPrimaryLocation W27454239351 @default.
• W2745423935 hasRelatedWork W1506200166 @default.
• W2745423935 hasRelatedWork W1995515455 @default.
• W2745423935 hasRelatedWork W2048182022 @default.
• W2745423935 hasRelatedWork W2080531066 @default.
• W2745423935 hasRelatedWork W2604872355 @default.
• W2745423935 hasRelatedWork W2748952813 @default.
• W2745423935 hasRelatedWork W2899084033 @default.
• W2745423935 hasRelatedWork W3031052312 @default.
• W2745423935 hasRelatedWork W3032375762 @default.
• W2745423935 hasRelatedWork W3108674512 @default.
• W2745423935 hasVolume "63" @default.
• W2745423935 isParatext "false" @default.
• W2745423935 isRetracted "false" @default.
• W2745423935 magId "2745423935" @default.
• W2745423935 workType "article" @default.